quinoxalines has been researched along with xl765 in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 22 (91.67) | 24.3611 |
| 2020's | 2 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Belousov, R; Brewer, KJ; Ghadimi, MP; Hoffman, A; Lazar, AJ; Lev, D; Liu, J; Lopez, G; Lusby, K; Pollock, RE; Torres, KE; Young, ED | 1 |
| Bao, X; Cai, F; Dai, C; Feng, M; Guo, K; Li, G; Lian, W; Liu, X; Ma, S; Ma, W; Wang, J; Wang, R; Xiao, J; Xing, B; Yang, Y; Yao, Y; Zhang, B; Zhang, H | 1 |
| Cohen, RB; Engelman, JA; Felip, E; Jänne, PA; Laird, AD; Macé, S; Martinez, P; Rockich, K; Ruiz-Soto, R; Shapiro, GI; Xu, J | 1 |
| Baselga, J; Egile, C; Laird, AD; Lorusso, PM; Markman, B; Miles, D; Papadopoulos, KP; Patnaik, A; Ruiz-Soto, R; Shi, W; Tabernero, J; Tolcher, AW | 1 |
| Abulafia, W; Bentzien, F; Buhr, CA; Chen, J; Chu, F; Dale, S; Du, X; Foster, P; Hsu, PP; Jaeger, CT; Laird, AD; Lam, ST; Lamb, P; Lee, M; Matthews, DJ; Plonowski, A; Qian, F; Shen, P; Won, KA; Wu, J; Yakes, FM; Yamaguchi, K; Young, J; Yu, P; Zhang, W | 1 |
| Abrisqueta, P; Bentzien, F; Egile, C; Jiang, J; Papadopoulos, KP; Rasco, D; Ruiz-Soto, R; Shi, W; Tabernero, J; Vose, JM | 1 |
| Ahluwalia, MS; Cloughesy, TF; Egile, C; Fathallah-Shaykh, HM; Jiang, J; Lager, JJ; Laird, AD; Mohile, N; Omuro, A; Tang, J; Wen, PY | 1 |
| Arimoto, T; Fujii, T; Fukuda, T; Ikeda, Y; Inaba, K; Kashiyama, T; Kawana, K; Kuramoto, H; Miyasaka, A; Oda, K; Osuga, Y; Sone, K; Uehara, Y; Wada-Hiraike, O; Yano, T | 1 |
| Boratyn, E; Durbas, M; Horwacik, I; Kamycka, E; Rokita, H | 1 |
| Colapietro, A; Festuccia, C; Gravina, GL; Jitariuc, A; Mancini, A; Marampon, F; Ricevuto, E; Scarsella, L; Vitale, F | 1 |
| Baars, JW; de Rooij, MF; Egile, C; Eldering, E; Jansen, MH; Kater, AP; Kersten, MJ; Kuijpers, TW; Kuil, A; Spaargaren, M; Ter Burg, J; Thijssen, R; van Bochove, GG; van Oers, MH; Virone-Oddos, A | 1 |
| Blackwell, K; Burris, H; Campana, F; Gao, L; Gomez, P; Isakoff, S; Jiang, J; Lynn Henry, N; Macé, S; Tolaney, SM | 1 |
| Aoki, K; Arimoto, T; Fujii, T; Fukuda, T; Ikeda, Y; Inaba, K; Kashiyama, T; Kawana, K; Makii, C; Miyasaka, A; Oda, K; Osuga, Y; Sone, K; Wada-Hiraike, O; Yano, T | 1 |
| Awan, FT; Costa, LJ; Gao, L; Gore, L; Lager, J; Sharma, J | 1 |
| Camisa, H; Dedieu, JF; Edelman, G; Ghuysen, AF; Lager, J; Liu, L; LoRusso, PM; Mehnert, JM; Sharma, J; Stein, M | 1 |
| Munakata, W; Tobinai, K | 1 |
| Ailawadhi, S; Arnason, J; Brown, JR; Doorduijn, JK; Egile, C; Gabrail, NY; Ganguly, S; Gao, L; Hamadani, M; Hayslip, J; Janssens, A; Kasar, S; Kater, AP; Kersten, MJ; Lager, JJ; Millenson, M; Offner, F; Ottmann, O; Tilly, H; Wagner-Johnston, N; Wu, B | 1 |
| Chen, T; Jin, M; Khishignyam, T; Kong, D; Qiu, Y; Wang, R; Wang, Z; Zhang, L; Zhang, Z; Zhou, C | 1 |
| Campana, F; Damstrup, L; Gandhi, L; Grande, E; Heist, RS; Hidalgo, M; Hyman, DM; Mita, MM; Schram, AM | 1 |
| Chen, SN; He, C; Wang, Q; Wu, P; Zhang, R | 1 |
| Rehan, M | 1 |
| Batsios, G; Gillespie, AM; Molloy, AR; Najac, C; Pieper, RO; Ronen, SM; Santos, RD; Subramani, E; Viswanath, P | 1 |
| Arend, RC; Birrer, MJ; Chimiczewski, P; Davis, AM; Ghamande, S; O'Malley, DM; Provencher, D; Vergote, I | 1 |
| Bertoni, F; Lupia, A; Stathis, A; Tarantelli, C | 1 |
1 review(s) available for quinoxalines and xl765
| Article | Year |
|---|---|
Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chromones; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Molecular Targeted Therapy; Oligopeptides; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinoxalines; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases | 2020 |
10 trial(s) available for quinoxalines and xl765
| Article | Year |
|---|---|
Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Prognosis; Protein Kinase Inhibitors; Quinazolines; Quinoxalines; Safety; Sulfonamides; Survival Rate; Tissue Distribution; TOR Serine-Threonine Kinases | 2014 |
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Monitoring; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases; Treatment Outcome; Young Adult | 2014 |
Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Area Under Curve; Diarrhea; Drug Resistance, Neoplasm; Exanthema; Female; Humans; Lymphoma; Male; MAP Kinase Signaling System; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasm Recurrence, Local; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Remission Induction; Sulfonamides; TOR Serine-Threonine Kinases; Treatment Outcome; Young Adult | 2015 |
Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glioma; Humans; Male; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Sulfonamides; Temozolomide; TOR Serine-Threonine Kinases; Treatment Outcome | 2015 |
Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Letrozole; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Staging; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retreatment; Sulfonamides; Treatment Outcome; Triazoles | 2015 |
Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Administration Schedule; Drug Monitoring; Drug Resistance, Neoplasm; Female; Humans; Leukemia, B-Cell; Lymphoma, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Recurrence; Retreatment; Rituximab; Sulfonamides; TOR Serine-Threonine Kinases; Treatment Outcome | 2016 |
A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Sulfonamides; Tablets | 2018 |
Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial.
Topics: Cohort Studies; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Quinoxalines; Sulfonamides | 2018 |
A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Neoplasms; Niacinamide; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Sulfonamides; TOR Serine-Threonine Kinases | 2018 |
EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinoxalines; Sulfonamides; TOR Serine-Threonine Kinases; Young Adult | 2020 |
13 other study(ies) available for quinoxalines and xl765
| Article | Year |
|---|---|
Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Humans; Mice; Nerve Sheath Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
Topics: Adenoma; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Drug Therapy, Combination; Female; Human Growth Hormone; Humans; Mice; Mice, Nude; Phosphoinositide-3 Kinase Inhibitors; Pituitary Neoplasms; Prolactin; Proto-Oncogene Proteins c-akt; Quinoxalines; Signal Transduction; Sulfonamides; Temozolomide; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2013 |
Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Disease Models, Animal; Humans; Inhibitory Concentration 50; Mice; Neoplasms; Neovascularization, Pathologic; Phosphatidylinositol Phosphates; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinoxalines; Ribosomal Protein S6 Kinases; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2014 |
Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Drug Synergism; Endometrial Neoplasms; Female; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Molecular Targeted Therapy; Niacinamide; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinoxalines; Sulfonamides; TOR Serine-Threonine Kinases | 2015 |
GD2 ganglioside specific antibody treatment downregulates PI3K/Akt/mTOR signaling network in human neuroblastoma cell lines.
Topics: Antibodies, Monoclonal; Apoptosis; Cell Line, Tumor; Drug Synergism; Gangliosides; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Neuroblastoma; Phosphatidylinositol 3-Kinases; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Quinolines; Quinoxalines; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases | 2015 |
Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Forkhead Box Protein O1; Glycogen Synthase Kinase 3 beta; Humans; Inhibitory Concentration 50; Male; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Quinoxalines; Receptors, Androgen; RNA, Small Interfering; Sirolimus; Sulfonamides; TOR Serine-Threonine Kinases | 2016 |
The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.
Topics: Adolescent; Adult; CD40 Antigens; Cell Adhesion; Cell Proliferation; Cell Survival; Cytokines; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; Purines; Quinazolinones; Quinoxalines; Sulfonamides; T-Lymphocytes; TOR Serine-Threonine Kinases | 2016 |
Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cystadenocarcinoma, Mucinous; Drug Screening Assays, Antitumor; Drug Synergism; Female; Fluorescence Resonance Energy Transfer; Humans; MAP Kinase Kinase Kinases; Models, Theoretical; Niacinamide; Ovarian Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Sulfonamides; TOR Serine-Threonine Kinases | 2016 |
Clinical development of voxtalisib: a pan-PI3K/mTOR inhibitor.
Topics: Clinical Trials as Topic; Drug Discovery; Humans; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases | 2018 |
In vitro anti-leukemia activity of dual PI3K/mTOR inhibitor Voxtalisib on HL60 and K562 cells, as well as their multidrug resistance counterparts HL60/ADR and K562/A02 cells.
Topics: Antineoplastic Agents; Cell Culture Techniques; Cell Cycle Checkpoints; Cell Proliferation; Cell Survival; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; HL-60 Cells; Humans; K562 Cells; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases | 2018 |
[Effect of PI3K/mTOR Signal Pathway Inhibitor XL765 on Human Leukemic KG-1 Cells].
Topics: Apoptosis; Cell Line, Tumor; Humans; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinoxalines; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases | 2019 |
Anticancer compound XL765 as PI3K/mTOR dual inhibitor: A structural insight into the inhibitory mechanism using computational approaches.
Topics: Binding Sites; Catalytic Domain; Class Ib Phosphatidylinositol 3-Kinase; Computer Simulation; Drug Screening Assays, Antitumor; Humans; Lysine; Methionine; Models, Molecular; Molecular Docking Simulation; Molecular Structure; Quinoxalines; Sulfonamides; TOR Serine-Threonine Kinases | 2019 |
PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival.
Topics: Adaptor Proteins, Signal Transducing; Animals; Astrocytes; Brain Neoplasms; Cell Cycle Proteins; Cell Line, Transformed; Glioma; Glucose; Glutamine; Glutarates; Humans; Isocitrate Dehydrogenase; Kaplan-Meier Estimate; Mice; Neoplasm Proteins; Nuclear Magnetic Resonance, Biomolecular; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Processing, Post-Translational; Quinoxalines; Ribosomal Protein S6 Kinases; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2019 |